Chronic Obstructive Pulmonary Disease (COPD)

Respiratory
26
Pipeline Programs
14
Companies
50
Clinical Trials
10 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
8
0
8
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 28 programs with unclassified modality

On Market (3)

Approved therapies currently available

AstraZeneca
DALIRESPApproved
roflumilast
AstraZeneca
Phosphodiesterase 4 Inhibitor [EPC]oral2011
U
ROFLUMILASTApproved
roflumilast
Unknown Company
Phosphodiesterase 4 Inhibitor [EPC]oral2023
U
TUDORZA PRESSAIRApproved
aclidinium bromide
Unknown Company
inhalation2012

Competitive Landscape

12 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
15 programs
1
2
4
2
Aclidinium bromidePhase 44 trials
Symbicort TurbuhalerPhase 45 trials
BFFPhase 31 trial
BGFPhase 35 trials
RoflumilastPhase 31 trial
+10 more programs
Active Trials
NCT03359122Completed10,067Est. Aug 2018
NCT01627743Completed505Est. Jan 2013
NCT00722267Completed7,400Est. Feb 2009
+24 more trials
Novartis
NovartisBASEL, Switzerland
4 programs
1
2
1
QVA149Phase 41 trial
Indacaterol 150 μgPhase 31 trial
QVA149Phase 31 trial
indacaterol/glycopyrrolatePhase 21 trial
Active Trials
NCT00558285Completed257Est. Jul 2008
NCT00846586Completed1,134Est. Mar 2010
NCT01285492Completed160Est. Sep 2012
+1 more trials
Design Therapeutics
1 program
1
Roflumilast alternated daysPhase 41 trial
Active Trials
NCT01849341CompletedEst. Jul 2014
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
AstegolimabPhase 3Monoclonal Antibody2 trials
Active Trials
NCT05878769Recruiting2,000Est. Jun 2027
NCT05595642Recruiting1,290Est. Sep 2027
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
TezepelumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06883305Recruiting990Est. Jun 2029
CT
3 programs
2
1
TQC3721 suspension for inhalationPhase 21 trial
TQC3721 inhalation powderPhase 11 trial
Tiotropium Bromide Inhalation PowderPhase 11 trial
Active Trials
NCT06748079RecruitingEst. Sep 2025
NCT06487416Active Not RecruitingEst. Oct 2024
NCT05292196TerminatedEst. Dec 2023
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK633Phase 21 trial
Active Trials
NCT00418613Completed266Est. Mar 2009
Genentech
GenentechCA - Oceanside
1 program
1
OmalizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT07059091Recruiting334Est. May 2031
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
OmalizumabPhase 2Monoclonal Antibody
Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
1 program
1
ReldesemtivPhase 2
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research StudiesN/A1 trial
The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD CohortN/A1 trial
Active Trials
NCT01776398Recruiting2,000Est. Dec 2028
NCT02838108Terminated452Est. Apr 2018
Rhythm Pharmaceuticals
1 program
Reveal LINQN/A1 trial
Active Trials
NCT04169529Completed42Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstraZenecaBGF
NovartisQVA149
AstraZenecaAclidinium bromide
Design TherapeuticsRoflumilast alternated days
AstraZenecaSymbicort Turbuhaler
AstraZenecaSymbicort Turbuhaler
AmgenTezepelumab
AstraZenecaBGF
AstraZenecaBGF
RocheAstegolimab
AstraZenecaTozorakimab 1
RocheAstegolimab
AstraZenecaBGF
AstraZenecaBGF
AstraZenecaBGF

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 73,990 patients across 50 trials

NCT07073950AstraZenecaBGF

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

Start: Nov 2025Est. completion: May 202756 patients
Phase 4Recruiting
NCT02603393NovartisQVA149

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Start: Nov 2015Est. completion: Jul 20171,053 patients
Phase 4Completed
NCT02153489AstraZenecaAclidinium bromide

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Start: Apr 2014Est. completion: Jun 201530 patients
Phase 4Completed
NCT01849341Design TherapeuticsRoflumilast alternated days

Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily

Start: Jul 2012Est. completion: Jul 2014
Phase 4Completed
NCT00576316AstraZenecaSymbicort Turbuhaler

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia

Start: Jan 2008Est. completion: Nov 2008201 patients
Phase 4Completed
NCT00542880AstraZenecaSymbicort Turbuhaler

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

Start: Sep 2007Est. completion: Aug 2008442 patients
Phase 4Completed
NCT06883305AmgenTezepelumab

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Start: Mar 2025Est. completion: Jun 2029990 patients
Phase 3Recruiting
NCT06283966AstraZenecaBGF

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Start: Feb 2024Est. completion: Mar 20285,000 patients
Phase 3Recruiting
NCT06075095AstraZenecaBGF

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

Start: Jan 2024Est. completion: Aug 2025297 patients
Phase 3Completed
NCT05878769RocheAstegolimab

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Start: Jun 2023Est. completion: Jun 20272,000 patients
Phase 3Recruiting
NCT05742802AstraZenecaTozorakimab 1

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

Start: Mar 2023Est. completion: May 20261,713 patients
Phase 3Active Not Recruiting
NCT05595642RocheAstegolimab

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Start: Dec 2022Est. completion: Sep 20271,290 patients
Phase 3Recruiting
NCT05573464AstraZenecaBGF

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Start: Sep 2022Est. completion: Mar 2024559 patients
Phase 3Completed
NCT04609904AstraZenecaBGF

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

Start: Mar 2021Est. completion: Mar 20252,187 patients
Phase 3Completed
NCT04609878AstraZenecaBGF

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

Start: Dec 2020Est. completion: Mar 20252,274 patients
Phase 3Completed
NCT04078126AstraZenecaBFF

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Start: Sep 2019Est. completion: Dec 202035 patients
Phase 3Completed
NCT03836677AstraZenecaBGF

A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

Start: Feb 2019Est. completion: Nov 201923 patients
Phase 3Completed
NCT01285492NovartisQVA149

Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start: Jan 2011Est. completion: Sep 2012160 patients
Phase 3Completed
NCT01044459AstraZenecaAclidinium bromide

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Start: Nov 2009Est. completion: Apr 2011605 patients
Phase 3Completed
NCT01001494AstraZenecaAclidinium bromide 400 μg bid

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Start: Oct 2009Est. completion: Nov 2010828 patients
Phase 3Completed
NCT00970268AstraZenecaAclidinium bromide

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Start: Aug 2009Est. completion: Oct 2010291 patients
Phase 3Completed
NCT00846586NovartisIndacaterol 150 μg

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Start: Mar 2009Est. completion: Mar 20101,134 patients
Phase 3Completed
NCT00839800AstraZenecaSymbicort Turbuhaler

Study to Investigate the Efficacy of Symbicort® SMART.

Start: Feb 2009Est. completion: Feb 20112,091 patients
Phase 3Completed
NCT00837967AstraZenecaSymbicort Turbuhaler

Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients

Start: Jan 2009Est. completion: Jul 200925 patients
Phase 3Completed
NCT00536731AstraZenecaSymbicort Turbuhaler

Symbicort Rapihaler Therapeutic Equivalence Study

Start: Sep 2007Est. completion: Apr 2008742 patients
Phase 3Completed
NCT00297102AstraZenecaRoflumilast

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Start: Feb 2006Est. completion: Sep 20081,523 patients
Phase 3Completed
NCT07059091GenentechOmalizumab

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Start: Feb 2026Est. completion: May 2031334 patients
Phase 2Recruiting
NCT05292196Chia Tai TianQing Pharmaceutical GroupTQC3721 suspension for inhalation

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

Start: May 2022Est. completion: Dec 2023
Phase 2Terminated
NCT01551888AstraZenecaAclidinium/formoterol 400/12μg

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Start: Jan 2012Est. completion: Mar 201224 patients
Phase 2Completed
NCT00868231AstraZenecaAclidinium bromide 400 μg bid

Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Start: Mar 2009Est. completion: Jul 200930 patients
Phase 2Completed
NCT00418613Merck & Co.MK633

A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

Start: Jan 2008Est. completion: Mar 2009266 patients
Phase 2Completed
NCT00558285Novartisindacaterol/glycopyrrolate

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Start: Nov 2007Est. completion: Jul 2008257 patients
Phase 2Completed
NCT06723756AstraZenecaBGF

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

Start: Jan 2025Est. completion: Jun 2025105 patients
Phase 1Completed
NCT06748079Chia Tai TianQing Pharmaceutical GroupTQC3721 inhalation powder

A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

Start: Dec 2024Est. completion: Sep 2025
Phase 1Recruiting
NCT06487416Chia Tai TianQing Pharmaceutical GroupTiotropium Bromide Inhalation Powder

A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions

Start: Jun 2024Est. completion: Oct 2024
Phase 1Active Not Recruiting
NCT06297668AstraZenecaBGF

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

Start: Apr 2024Est. completion: Jun 202442 patients
Phase 1Completed
NCT05569421AstraZenecaBGF

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Start: Oct 2022Est. completion: Apr 2023108 patients
Phase 1Completed
NCT05477108AstraZenecaBGF

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Start: Jul 2022Est. completion: Apr 2023108 patients
Phase 1Completed
NCT03276052AstraZenecaAclidinium bromide

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Start: Oct 2021Est. completion: Nov 202120 patients
Phase 1Completed
NCT03906045AstraZenecaBGF

A Scintigraphy Study of PT010 in COPD Patients

Start: Apr 2019Est. completion: Mar 202018 patients
Phase 1Completed
NCT03740373AstraZenecaBGF

A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

Start: Sep 2018Est. completion: Oct 201810 patients
Phase 1Completed
NCT00788645AstraZenecaCOPD self care advice

The Use of a Forecasting System for Predicting Exacerbations of COPD

Start: Aug 2008Est. completion: Mar 200998 patients
Phase 1Completed
NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow

Study of Patient With Frequent Exacerbations in Moscow

Start: Nov 2025Est. completion: Jun 2027500 patients
N/ARecruiting
NCT07414134AstraZenecaBGF

Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

Start: Oct 2025Est. completion: Nov 20253,598 patients
N/ACompleted
NCT06712563AstraZenecaBGF

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Start: Apr 2025Est. completion: Sep 20262,000 patients
N/ARecruiting
NCT07221981AstraZenecaStudy of Patient With Frequent COPD Exacerbations

Study of Patient With Frequent COPD Exacerbations

Start: Dec 2024Est. completion: Jun 20262,000 patients
N/ARecruiting
NCT06511193AstraZenecaBGF

Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

Start: Sep 2024Est. completion: May 2026152 patients
N/AActive Not Recruiting
NCT07103642AstraZenecaBGF

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

Start: Aug 2024Est. completion: Oct 20243,402 patients
N/ACompleted
NCT06742736AstraZenecaBGF

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

Start: May 2024Est. completion: Sep 202413,000 patients
N/ACompleted
NCT06744374AstraZenecaBGF

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

Start: Feb 2024Est. completion: Mar 202422,369 patients
N/ACompleted

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals
10 actively recruiting trials targeting 73,990 patients
14 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)Pulmonary Fibrosis(15)